Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO 8539

Drug Profile

ONO 8539

Alternative Names: ONO-8539

Latest Information Update: 03 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Hyogo College of Medicine; Ono Pharmaceutical
  • Class
  • Mechanism of Action Prostaglandin-E EP1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux; Overactive bladder

Most Recent Events

  • 25 Nov 2014 Phase-I/II clinical trials in Gastro-oesophageal reflux in Japan (PO) (UMIN000015753)
  • 31 Mar 2014 Ono Pharmaceutical completes a phase I trial in Healthy volunteers in United Kingdom (NCT01705275)
  • 16 Jan 2014 Ono Pharmaceutical completes enrolment in its phase I trial in Healthy volunteers in United Kingdom (NCT01705275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top